Sarepta Therapeutics (SRPT) Says USPTO Issued Favorable Decisions on Exon 51 and Exon 53 Composition in Case vs BioMarin (BMRN)
September 20, 2016 5:17 PM
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the Patent Trial and Appeal Board ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
